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after discharge, the first month and the first 3 months. The per-
centage was subtracted from 100 to obtain the percentage of non-
adherent days, so that the hazard ratios (HR) in the Cox propor-
tional hazards models reflected risk associated with poorer ad-
herence. For patients who had an MACE or who died in the first 
3 months, adherence was computed up until the week of the event. 
Medical covariates included the Charlson comorbidity index  [15] 
and left ventricular ejection fraction (normal/mild dysfunction: 
 6 40%; moderate/severe dysfunction:  ! 40%)  [16] . Partial correla-
tions and Cox proportional hazards models were used, adjusting 
for age and sex, treating study site as stratum. All continuous pre-
dictors were standardized. The degree of mediation was assessed 
by the percent reduction in the Cox regression coefficient for de-
pressive symptoms when aspirin adherence was included in the 
model. 
 The COPES parent study included 457 ACS patients, of which 
172 took part in the aspirin monitoring study. Refusers of the 
monitoring study had higher levels of in-hospital depressive 
symptoms  [12] . Four patients had an MACE within the first 7 days 
after discharge and were excluded from the present analyses. The 
mean age was 59.4 years (SD = 12.2 years), 45% of the patients were 
female and 86% white.
 Controlling for age, sex and site, baseline depressive symp-
toms were significantly correlated with poorer 7-day, 1-month 
and 3-month aspirin adherence (partial r: 0.22, 0.26 and 0.19, re-
spectively; all p  ! 0.02). After 1 year, there had been 14 MACE/
ACM events (8%). Adjusting for age, sex and site, poorer 7-day 
(adjusted standardized HR, sHR: 1.76; CI: 1.14–2.73) and 1-month 
aspirin adherence (adjusted sHR: 1.75; CI: 1.18–2.60) as well as 
baseline depressive symptoms (adjusted sHR: 1.53; CI: 1.02–2.29) 
were each individually associated with 1-year MACE/ACM. A 
similar, yet nonsignificant association was found for poorer 
3-month aspirin adherence (adjusted sHR: 1.45; CI: 0.97–2.17; p = 
0.054). When both baseline depressive symptoms and 7-day aspi-
rin adherence were entered into the age- and sex-adjusted model, 
the HR for depressive symptoms decreased substantially (adjust-
ed sHR: 1.34; CI: 0.89–2.01), whereas poorer 7-day aspirin adher-
ence remained a significant predictor (adjusted sHR: 1.64; CI: 
1.06–2.54). The effect size for depressive symptoms decreased by 
31% ( fig.  1 ) when 7-day aspirin adherence was included in the 
analysis. Controlling for left ventricular ejection fraction and 
Charlson comorbidity index did not alter these results (data not 
shown). Similarly, poorer 1-month aspirin adherence decreased 
the effect size for baseline depressive symptoms by 29% (adjusted 
sHR for depressive symptoms: 1.37; CI: 0.88–2.13; adjusted sHR 
for poorer 1-month adherence: 1.65; CI: 1.11–2.45). 
 Depression in cardiac patients has been linked to several bio-
logical and behavioral dysregulations  [16, 17] . The present study 
shows that a modifiable patient behavior – medication adher-
ence – may account for some of the clinical outcome risk associ-
ated with increased depressive symptoms after ACS. The Heart 
and Soul Study, which tested biological and behavioral depression 
 In survivors of acute coronary syndromes (ACS; unstable an-
gina or myocardial infarction), depression is highly prevalent  [1] 
and increases the risk of adverse medical outcomes, independent 
of other prognostic risk markers  [2, 3] . After ACS, adherence to 
recommended medications (e.g. aspirin, statins and   -blockers) 
is crucial to prevent recurrent events or mortality  [4–6] , yet rates 
of adherence to these medications are poor  [7–9] . Depressed pa-
tients are especially likely to be poorly adherent  [8–11] . Thus, poor 
medication adherence may explain some of the increased risk of 
depression and adverse clinical outcomes after ACS.
 We used data from 168 participants in the medication moni-
toring substudy  [12] of the observational Coronary Psychosocial 
Evaluation Studies (COPES)  [13] to test this hypothesis. This sub-
study included hospitalized ACS patients who were prescribed a 
daily dose of aspirin, neither used a weekly pillbox nor lived in a 
nursing home, and had a score of  6 10 or  ! 5 on the Beck Depres-
sion Inventory  [14] (see Rieckmann et al.  [12] for study sample 
characteristics and eligibility criteria, and Davidson et al.  [13] for 
details on outcome event ascertainment). Aspirin adherence over 
90 days after hospital discharge was measured using the Medica-
tion Event Monitoring System (MEMS; APREX Corp., Fremont, 
Calif., USA) device. Each time the MEMS bottle is opened, the 
date and time is permanently recorded on a computer chip in the 
cap. Patients received a 90-day supply of their prescribed aspirin 
dose in an MEMS bottle. They were informed that their adherence 
was being monitored, but they did not receive adherence counsel-
ing. The outcome was the 1-year first occurrence of a major ad-
verse cardiac event (MACE; nonfatal myocardial infarction, ur-
gent cardiac revascularization or unstable angina hospitalization) 
or all-cause mortality (ACM). The study complies with the Dec-
laration of Helsinki. The institutional review boards of each study 
site approved the study  [12] .
 Adherence, defined as the percentage of days the correct num-
ber of pills (1) was taken, was computed across the first 7 days 
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mediators in a sample of 1,017 patients with stable coronary heart 
disease  [18] , found that self-reported medication adherence ex-
plained only a small portion (5%) of the association between de-
pressive symptoms and future clinical events, as opposed to 31% 
in our study. However, different mechanisms may account for the 
increased risk in depressed stable heart disease patients (the pop-
ulation of the Heart and Soul Study) as compared to depressed 
ACS patients. Also, electronic monitoring in our study provided 
a more objective measure of adherence and yielded higher nonad-
herence rates in comparison to the Heart and Soul Study  [12] . In 
addition, our follow-up was shorter than that in the Heart and 
Soul Study, and the impact of adherence on event-free survival 
may decrease over time. 
 Generalizability of the current study is limited by the relatively 
small sample size. Also, the study participants had lower levels of 
depressive symptoms than the study refusers  [12] , and the restric-
tion of range may have attenuated both the associations between 
adherence and depression, and between depressive symptoms and 
MACE/ACM. It also remains to be shown whether poor aspirin 
adherence is a marker of overall poor medication adherence across 
all cardioprotective medications  [6] . Lastly, it is possible that aspi-
rin, due to anti-inflammatory effects, may reduce depressive 
symptoms. A recent case-control study of a sample of 345 commu-
nity-dwelling women showed that the use of aspirin was associated 
with a significantly decreased incidence of major depressive disor-
der after the age of 50 years  [19] . In the current COPES substudy, 
however, we had previously found that higher aspirin adherence 
was not associated with subsequent improvements in depressive 
symptoms over time; in fact, changes in depressive symptoms pre-
ceded changes in aspirin adherence, but not vice versa  [12] . Still, it 
is possible that better aspirin adherence may lead to later changes 
in depressive symptoms in the long run. This will need to be ex-
plored in future studies with repeated assessments of depressive 
symptoms further away from the index ACS event.
 In conclusion, this study provides evidence that poorer aspirin 
adherence may account for a substantial part of the excess prog-
nostic risk associated with depressive symptoms after ACS. Pro-
moting medication adherence in combination with depression 
treatment may more effectively improve the medical prognosis for 
depressed patients than simply treating depression. 
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Significant at p < 0.05
The strength of the association is reduced when
the mediator is included in the model
b
 Fig. 1. The effect of in-hospital depressive symptoms on MACE/
ACM is reduced by 31% when aspirin adherence is added as a pre-
dictor. The correlation and the HR are adjusted for age and sex, 
with study site treated as stratum.  a Direct effect model.  b Me-
diational model. 
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